Evolva has acquired resveratrol – an on-market high value ingredient made by yeast fermentation. The product is expected to make a positive contribution to Evolva’s cash flow starting 2014. The product has consolidated Evolva's strengths in yeast fermentation technologies and capabilities. A Non-binding investor commitment to fund resveratrol activities has been put in place for next 18 months. Transaction supports financing round - expected to complete Q1 2013. Evolva has streamlined portfolio internal focus on vanilla/resveratrol and stevia/saffron pathways.
